纯度锐度再攀升！港股创新药指数迎来新调整

Core Viewpoint - The adjustment of the Guozheng Hong Kong Stock Connect Innovative Drug Index aims to enhance its investment value by excluding CXO companies and increasing the frequency of index adjustments, reflecting the latest trends in China's innovative drug industry [1][2]. Group 1: Index Adjustment Details - The sample space will now include stocks primarily engaged in innovative drug research and production, excluding CXO companies [1]. - The sample stocks will undergo quarterly adjustments, implemented on the next trading day after the second Friday of March, June, September, and December each year [1]. Group 2: Market Insights - The ETF manager believes that the refined index will better represent industry leaders and the trend of domestic innovative drug companies going global, providing higher investment elasticity [2]. - The innovative drug sector is experiencing a growth phase, with any quality innovative drug company potentially attracting capital through product upgrades [2]. Group 3: Future Outlook - In the short term, the positive fundamentals of the innovative drug industry are expanding, with potential value reassessment for generic innovative drug companies [2]. - The long-term investment value of innovative drugs is supported by the industry's improving conditions, with significant increases in BD transaction amounts since 2025 [2]. Group 4: ETF Performance - Recent trading volumes indicate strong investor interest, with the Silverhua Fund's innovative drug ETF achieving a transaction volume of over 707 million yuan and the Hong Kong innovative drug ETF reaching 2.73 billion yuan on July 29 [2]. - The innovative drug sector continues to show upward investment value as industry conditions improve [2].